US4985241A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic combination of free-radical scavenger and tumor necrosis factor
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1989-08-25
•
Granted: 1991-01-15
•
Expires: 2009-08-25
Abstract
Abstract Damage to cells, tissue and other body parts in a mammalian host may be treated by using a lymphokine or cytotoxin in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The lymphokine or cytotoxin is preferably tumor necrosis factor and the biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.
Inventors
- 👤 Robert Zimmerman
- 👤 Benedict J. Marafino, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 04:47
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/191
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
75 words
A composition suitable for administration to mammalian hosts for therapeutic or prophylactic treatment of biological damage to the host caused by free radical generation, which composition comprises a mixture, in pharmacologically effective amounts, of Tumor Necrosis Factor from a mammalian species and at least one biological modifier that is a free radical scavenger selected from the group consisting of buthionine sulphoximine, uric acid or vitamin C, or combinations of one or more of these modifiers.
Claim 2
Dependent Claim
75 words
A composition suitable for administration to mammalian hosts for therapeutic or prophylactic treatment of biological damage to the host caused by free radical generation, which composition comprises a mixture, in pharmacologically effective amounts, of Tumor Necrosis Factor from a mammalian species and at least one biological modifier that is a free radical scavenger selected from the group consisting of buthionine sulphoximine, uric acid or vitamin C, or combinations of one or more of these modifiers.
Claim 3
Dependent Claim
12 words
The composition of claim 1 further comprising a pharmaceutically acceptable carrier medium.
Claim 4
Dependent Claim
14 words
The composition of claim 1 wherein the Tumor Necrosis Factor is tumor necrosis factor-alpha.
Claim 5
Dependent Claim
17 words
The composition of claim 3 wherein the tumor necrosis factor-alpha is recombinant and from a human source.
Claim 6
Dependent Claim
13 words
The composition of claim 4 wherein the tumor necrosis factor-alpha is a mutein.
Claim 7
Dependent Claim
23 words
The composition of claim 5 wherein the mutein has the first four or the first eight amino acids deleted from the N-terminus thereof.
Claim 8
Dependent Claim
11 words
The composition of claim 1 wherein the biological damage is cancer.
Claim 9
Independent Claim
57 words
A method for the therapeutic or prophylactic treatment of biological damage to a mammalian host caused by free radical generation, which method comprises administering to the host pharmacologically effective amounts of at least one lymphokine or cytotoxin from a mammalian species and at least one biological modifier selected from a free radical scavenger or a metabolic inhibitor.
Claim 10
Independent Claim
57 words
A method for the therapeutic or prophylactic treatment of biological damage to a mammalian host caused by free radical generation, which method comprises administering to the host pharmacologically effective amounts of at least one lymphokine or cytotoxin from a mammalian species and at least one biological modifier selected from a free radical scavenger or a metabolic inhibitor.
Claim 11
Dependent Claim
27 words
The method of claim 8 wherein the Tumor Necrosis Factor and the biological modifier are administered separately to the host, and the biological modifier is administered first.
Claim 12
Dependent Claim
14 words
The method of claim 1 wherien the Tumor Necrosis Factor is tumor necrosis factor-alpha.
Claim 13
Dependent Claim
17 words
The method of claim 10 wherein the tumor necrosis factor-alpha is recombinant and from a human source.
Claim 14
Dependent Claim
13 words
The method of claim 11 wherein the tumor necrosis factor-alpha is a mutein.
Claim 15
Dependent Claim
23 words
The method of claim 12 wherein the mutein has the first four or the first eight amino acids deleted from the N-terminus thereof.
Claim 16
Dependent Claim
13 words
The method of claim 1 wherein the biological damage being treated is cance.
Claim 17
Dependent Claim
45 words
The method of claim 1 wherein the tumor necrosis factor-alpha is administered in an amount of 25 to 100 μg/m 2 host and the buthionine sulphoximine is administered in a pharmacologically effective amount before and during the course of administration of the tumor necrosis factor-alpha.
Claim 18
Dependent Claim
39 words
The method of claim 1 wherein the tumor necrosis factor-alpha is administered in an amount of 125 μg/m 2 host and the vitamin C is administered in a pharmocologially effective amount prior to administration of the tumor necrosis factor-alpha.
Claim 19
Dependent Claim
39 words
The method of claim 1 wherein the tumor necrosis factor-alpha is administered in an amount of 25-100 μg/m 2 host and the uric acid is administered in a pharmocologically effective amount prior to administration of the tumor necrosis factor-alpha.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-14 | 1994-07-16 | 1995-01-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-14 | 1998-07-16 | 1999-01-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-14 | 2002-07-16 | 2003-01-15 | $7700.00 | Window Closed / Lapsed |